Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing...

Area of Science:

• Health Services Research
• Pharmaceutical Policy Analysis

Background:

• Medicaid policies significantly influence healthcare utilization.
• Understanding the impact of drug reimbursement restrictions is crucial for public health.

Purpose of the Study:

• To evaluate the effect of a Florida Medicaid policy limiting anti-ulcer drug reimbursement.
• To assess changes in anti-ulcer drug use and peptic ulcer disease hospitalizations.

Main Methods:

• Observational study using Florida Medicaid claims and hospital discharge data (1989-1993).
• Poisson regression model compared pre- and post-policy changes in drug reimbursement and hospitalization rates.
• Analysis included both Medicaid and non-Medicaid patients.

Main Results:

• Medicaid reimbursement for anti-ulcer drugs dropped by 33% post-policy (p < .001).
• No significant increase in Medicaid peptic ulcer disease-related hospitalizations was observed.
• Outpatient anti-ulcer drug use decreased substantially.

Conclusions:

• Florida's policy effectively reduced outpatient anti-ulcer drug use among Medicaid recipients.
• The policy did not lead to an increase in hospitalizations for peptic ulcer conditions.
• This suggests that restricting reimbursement can curb drug utilization without compromising patient outcomes for peptic ulcer disease.